Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jacob Laubach, M.D.

Co-Author

This page shows the publications co-authored by Jacob Laubach and Paul Richardson.
Connection Strength

23.527
  1. Phase 1 open-label study of panobinostat, lenalidomide, bortezomib?+?dexamethasone in relapsed and relapsed/refractory multiple myeloma. Blood Cancer J. 2021 02 05; 11(2):20.
    View in: PubMed
    Score: 0.951
  2. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol. 2021 01; 22(1):142-154.
    View in: PubMed
    Score: 0.941
  3. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol. 2017 08; 178(4):547-560.
    View in: PubMed
    Score: 0.733
  4. Deacetylase inhibitors: an advance in myeloma therapy? Expert Rev Hematol. 2017 Mar; 10(3):229-237.
    View in: PubMed
    Score: 0.721
  5. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2016 05; 30(5):1005-17.
    View in: PubMed
    Score: 0.668
  6. Panobinostat for the Treatment of Multiple Myeloma. Clin Cancer Res. 2015 Nov 01; 21(21):4767-73.
    View in: PubMed
    Score: 0.654
  7. CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. Clin Cancer Res. 2015 Jun 15; 21(12):2660-2.
    View in: PubMed
    Score: 0.636
  8. The challenge of cross-trial comparisons using limited data. Haematologica. 2014 Aug; 99(8):e145-6.
    View in: PubMed
    Score: 0.606
  9. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):97-111.
    View in: PubMed
    Score: 0.585
  10. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
    View in: PubMed
    Score: 0.498
  11. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol. 2011 Feb; 4(1):51-60.
    View in: PubMed
    Score: 0.475
  12. Hematology: Bortezomib and dexamethasone induction for multiple myeloma. Nat Rev Clin Oncol. 2011 Jan; 8(1):8-10.
    View in: PubMed
    Score: 0.473
  13. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
    View in: PubMed
    Score: 0.433
  14. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009 Dec; 23(12):2222-32.
    View in: PubMed
    Score: 0.432
  15. Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17.
    View in: PubMed
    Score: 0.431
  16. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma. 2009 May; 50(5):694-702.
    View in: PubMed
    Score: 0.421
  17. Maximizing the clinical benefit of novel therapies in multiple myeloma. Oncology (Williston Park). 2009 Apr 30; 23(5):415-6, 419.
    View in: PubMed
    Score: 0.421
  18. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021 Sep 24.
    View in: PubMed
    Score: 0.249
  19. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021 Aug 01; 39(22):2430-2442.
    View in: PubMed
    Score: 0.244
  20. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021 May 28.
    View in: PubMed
    Score: 0.243
  21. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e105-e118.
    View in: PubMed
    Score: 0.239
  22. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2021 03 01; 39(7):757-767.
    View in: PubMed
    Score: 0.235
  23. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 08 20; 136(8):936-945.
    View in: PubMed
    Score: 0.230
  24. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253.
    View in: PubMed
    Score: 0.217
  25. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. Eur J Haematol. 2019 Jun; 102(6):494-503.
    View in: PubMed
    Score: 0.211
  26. Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. Br J Haematol. 2019 08; 186(3):e35-e39.
    View in: PubMed
    Score: 0.209
  27. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 2019 07; 33(7):1736-1746.
    View in: PubMed
    Score: 0.207
  28. The power of proteasome inhibition in multiple myeloma. Expert Rev Proteomics. 2018 12; 15(12):1033-1052.
    View in: PubMed
    Score: 0.204
  29. Ixazomib for the treatment of multiple myeloma. Expert Opin Pharmacother. 2018 Dec; 19(17):1949-1968.
    View in: PubMed
    Score: 0.204
  30. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018 11 09; 8(11):109.
    View in: PubMed
    Score: 0.204
  31. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2019 01 15; 25(2):478-486.
    View in: PubMed
    Score: 0.202
  32. Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2018 10; 32(10):2305.
    View in: PubMed
    Score: 0.202
  33. The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 2018 Aug; 16(8):564-574.
    View in: PubMed
    Score: 0.200
  34. Maintenance and continuous therapy for multiple myeloma. Expert Rev Anticancer Ther. 2018 08; 18(8):751-764.
    View in: PubMed
    Score: 0.199
  35. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol. 2018 08; 182(4):495-503.
    View in: PubMed
    Score: 0.197
  36. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. Br J Haematol. 2018 05; 181(4):433-446.
    View in: PubMed
    Score: 0.197
  37. Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. Leukemia. 2018 09; 32(9):2032-2036.
    View in: PubMed
    Score: 0.194
  38. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. Br J Haematol. 2018 03; 180(6):821-830.
    View in: PubMed
    Score: 0.193
  39. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017 12; 36(4):561-584.
    View in: PubMed
    Score: 0.191
  40. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. Br J Haematol. 2018 01; 180(1):41-51.
    View in: PubMed
    Score: 0.190
  41. New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. J Blood Med. 2017; 8:107-121.
    View in: PubMed
    Score: 0.187
  42. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. Br J Haematol. 2017 09; 178(5):756-763.
    View in: PubMed
    Score: 0.184
  43. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2017 12; 31(12):2695-2701.
    View in: PubMed
    Score: 0.184
  44. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. Clin Pharmacol Ther. 2017 Jan; 101(1):81-88.
    View in: PubMed
    Score: 0.179
  45. Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. Pharmacol Res. 2017 03; 117:185-191.
    View in: PubMed
    Score: 0.178
  46. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther. 2016 10; 16(10):1291-301.
    View in: PubMed
    Score: 0.174
  47. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016 10 06; 128(14):1821-1828.
    View in: PubMed
    Score: 0.174
  48. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood. 2016 06 02; 127(22):2693-700.
    View in: PubMed
    Score: 0.170
  49. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016 Feb 11; 127(6):681-95.
    View in: PubMed
    Score: 0.166
  50. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Rev Clin Pharmacol. 2016; 9(1):35-48.
    View in: PubMed
    Score: 0.165
  51. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24; 373(13):1207-19.
    View in: PubMed
    Score: 0.163
  52. Correction to: Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther. 2015; 15(9):1121.
    View in: PubMed
    Score: 0.162
  53. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther. 2015; 15(7):737-48.
    View in: PubMed
    Score: 0.161
  54. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
    View in: PubMed
    Score: 0.160
  55. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer. 2015 Sep; 23(9):2789-97.
    View in: PubMed
    Score: 0.157
  56. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncol. 2015; 11(8):1153-68.
    View in: PubMed
    Score: 0.156
  57. Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):255-61.
    View in: PubMed
    Score: 0.155
  58. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014 Dec; 15(13):1503-1512.
    View in: PubMed
    Score: 0.154
  59. Novel targeted agents in the treatment of multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):903-25.
    View in: PubMed
    Score: 0.152
  60. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug 14; 124(7):1038-46.
    View in: PubMed
    Score: 0.150
  61. Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs. 2014 Apr; 23(4):445-52.
    View in: PubMed
    Score: 0.147
  62. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther. 2013 Dec; 13(12):1731-40.
    View in: PubMed
    Score: 0.144
  63. Clinical translation in multiple myeloma: from bench to bedside. Semin Oncol. 2013 Oct; 40(5):549-53.
    View in: PubMed
    Score: 0.143
  64. IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities. Oncology (Williston Park). 2013 Aug; 27(8):803-4, 806.
    View in: PubMed
    Score: 0.141
  65. Kidney disease and multiple myeloma. Clin J Am Soc Nephrol. 2013 Nov; 8(11):2007-17.
    View in: PubMed
    Score: 0.141
  66. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013 Jul; 37(7):829-37.
    View in: PubMed
    Score: 0.138
  67. Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood. 2013 Jan 31; 121(5):858.
    View in: PubMed
    Score: 0.136
  68. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7.
    View in: PubMed
    Score: 0.135
  69. New proteasome inhibitors in myeloma. Curr Hematol Malig Rep. 2012 Dec; 7(4):258-66.
    View in: PubMed
    Score: 0.135
  70. Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone. J Clin Oncol. 2012 Jul 10; 30(20):e175-9.
    View in: PubMed
    Score: 0.131
  71. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
    View in: PubMed
    Score: 0.128
  72. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
    View in: PubMed
    Score: 0.127
  73. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
    View in: PubMed
    Score: 0.126
  74. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9.
    View in: PubMed
    Score: 0.125
  75. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62.
    View in: PubMed
    Score: 0.122
  76. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
    View in: PubMed
    Score: 0.122
  77. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood. 2011 Jul 21; 118(3):535-43.
    View in: PubMed
    Score: 0.121
  78. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011 May 10; 29(14):1916-23.
    View in: PubMed
    Score: 0.120
  79. Hematology: Setting the standard for newly diagnosed multiple myeloma. Nat Rev Clin Oncol. 2011 May; 8(5):255-6.
    View in: PubMed
    Score: 0.120
  80. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.
    View in: PubMed
    Score: 0.119
  81. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011 Feb; 152(4):367-79.
    View in: PubMed
    Score: 0.118
  82. Multiple myeloma. Annu Rev Med. 2011; 62:249-64.
    View in: PubMed
    Score: 0.118
  83. Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45.
    View in: PubMed
    Score: 0.114
  84. The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009.
    View in: PubMed
    Score: 0.113
  85. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
    View in: PubMed
    Score: 0.111
  86. The evolution and impact of therapy in multiple myeloma. Med Oncol. 2010 Jun; 27 Suppl 1:S1-6.
    View in: PubMed
    Score: 0.111
  87. Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Canc Netw. 2010 Feb; 8 Suppl 1:S4-S12.
    View in: PubMed
    Score: 0.111
  88. Hematology: Thalidomide maintenance in multiple myeloma. Nat Rev Clin Oncol. 2009 Oct; 6(10):565-6.
    View in: PubMed
    Score: 0.108
  89. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009 Apr; 46(2):166-75.
    View in: PubMed
    Score: 0.105
  90. Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma. Clin Cancer Res. 2021 Sep 13.
    View in: PubMed
    Score: 0.062
  91. Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Jun 26.
    View in: PubMed
    Score: 0.061
  92. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Rep. 2021 01 05; 34(1):108532.
    View in: PubMed
    Score: 0.059
  93. Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 12; 20(12):797-803.
    View in: PubMed
    Score: 0.057
  94. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
    View in: PubMed
    Score: 0.057
  95. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 Jun; 7(6):e447-e455.
    View in: PubMed
    Score: 0.057
  96. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389.
    View in: PubMed
    Score: 0.057
  97. A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clin Cancer Res. 2020 01 15; 26(2):344-353.
    View in: PubMed
    Score: 0.054
  98. Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. Am J Hematol. 2019 05; 94(5):E146-E149.
    View in: PubMed
    Score: 0.052
  99. Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. J Geriatr Oncol. 2019 05; 10(3):486-489.
    View in: PubMed
    Score: 0.051
  100. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2019 01; 60(1):118-123.
    View in: PubMed
    Score: 0.050
  101. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
    View in: PubMed
    Score: 0.049
  102. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841.
    View in: PubMed
    Score: 0.049
  103. Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2018 07; 53(7):942-945.
    View in: PubMed
    Score: 0.048
  104. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Br J Haematol. 2018 01; 180(2):271-275.
    View in: PubMed
    Score: 0.047
  105. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. JAMA Oncol. 2017 Jul 01; 3(7):980-988.
    View in: PubMed
    Score: 0.046
  106. IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol. 2017 Aug; 92(8):746-751.
    View in: PubMed
    Score: 0.046
  107. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Apr 28; 374(17):1621-34.
    View in: PubMed
    Score: 0.043
  108. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18.
    View in: PubMed
    Score: 0.040
  109. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015 Jun; 55(6 Pt 2):1545-54.
    View in: PubMed
    Score: 0.039
  110. Management of relapsed multiple myeloma after autologous stem cell transplant. Biol Blood Marrow Transplant. 2015 May; 21(5):793-8.
    View in: PubMed
    Score: 0.039
  111. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61.
    View in: PubMed
    Score: 0.038
  112. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol. 2014 Oct; 167(1):127-31.
    View in: PubMed
    Score: 0.037
  113. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9.
    View in: PubMed
    Score: 0.037
  114. Evolving strategies in the initial treatment of multiple myeloma. Semin Oncol. 2013 Oct; 40(5):592-601.
    View in: PubMed
    Score: 0.036
  115. Phase transitions in human IgG solutions. J Chem Phys. 2013 Sep 28; 139(12):121904.
    View in: PubMed
    Score: 0.036
  116. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8.
    View in: PubMed
    Score: 0.035
  117. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013 Apr 11; 121(15):2975-87.
    View in: PubMed
    Score: 0.034
  118. Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. Br J Haematol. 2012 Nov; 159(3):340-51.
    View in: PubMed
    Score: 0.033
  119. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res. 2012; 4:253-68.
    View in: PubMed
    Score: 0.033
  120. Pathological crystallization of human immunoglobulins. Proc Natl Acad Sci U S A. 2012 Aug 14; 109(33):13359-61.
    View in: PubMed
    Score: 0.033
  121. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012 Feb 21; 9(3):135-43.
    View in: PubMed
    Score: 0.032
  122. Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8.
    View in: PubMed
    Score: 0.032
  123. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8.
    View in: PubMed
    Score: 0.030
  124. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011 Apr 28; 117(17):4409-19.
    View in: PubMed
    Score: 0.030
  125. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb; 152(4):420-32.
    View in: PubMed
    Score: 0.030
  126. Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies. Blood. 2010 Jul 29; 116(4):593-602.
    View in: PubMed
    Score: 0.028
  127. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.